{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T14:39:35Z","timestamp":1786372775708,"version":"build-2736575974"},"reference-count":35,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["CJASN"],"published-print":{"date-parts":[[2017,9]]},"abstract":"\n Background and objectives<\/jats:title>\n Increases in fibroblast growth factor 23 precede kidney function decline in autosomal dominant polycystic kidney disease; however, the role of fibroblast growth factor 23 in autosomal dominant polycystic kidney disease has not been well characterized.<\/jats:p>\n <\/jats:sec>\n \n Design, setting, participants & measurements<\/jats:title>\n \n We measured intact fibroblast growth factor 23 levels in baseline serum samples from 1002 participants in the HALT-PKD Study A (\n n<\/jats:italic>\n =540; mean eGFR =91\u00b117 ml\/min per 1.73 m\n 2<\/jats:sup>\n ) and B (\n n<\/jats:italic>\n =462; mean eGFR =48\u00b112 ml\/min per 1.73 m\n 2<\/jats:sup>\n ). We used linear mixed and Cox proportional hazards models to test associations between fibroblast growth factor 23 and eGFR decline, percentage change in height-adjusted total kidney volume, and composite of time to 50% reduction in eGFR, onset of ESRD, or death.\n <\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n Median (interquartile range) intact fibroblast growth factor 23 was 44 (33\u201356) pg\/ml in HALT-PKD Study A and 69 (50\u201393) pg\/ml in Study B. In adjusted models, annualized eGFR decline was significantly faster in the upper fibroblast growth factor 23 quartile (Study A: quartile 4, \u22123.62; 95% confidence interval, \u22124.12 to \u22123.12 versus quartile 1, \u22122.51; 95% confidence interval, \u22122.71 to \u22122.30 ml\/min per 1.73 m\n 2<\/jats:sup>\n ;\n P<\/jats:italic>\n for trend <0.001; Study B: quartile 4, \u22123.74; 95% confidence interval, \u22124.14 to \u22123.34 versus quartile 1, \u22122.78; 95% confidence interval, \u22122.92 to \u22122.63 ml\/min per 1.73 m\n 2<\/jats:sup>\n ;\n P<\/jats:italic>\n for trend <0.001). In Study A, higher fibroblast growth factor 23 quartiles were associated with greater longitudinal percentage increase in height-adjusted total kidney volume in adjusted models (quartile 4, 6.76; 95% confidence interval, 5.57 to 7.96 versus quartile 1, 6.04; 95% confidence interval, 5.55 to 6.54;\n P<\/jats:italic>\n for trend =0.03). In Study B, compared with the lowest quartile, the highest fibroblast growth factor 23 quartile was associated with elevated risk for the composite outcome (hazard ratio, 3.11; 95% confidence interval, 1.84 to 5.25). Addition of fibroblast growth factor 23 to a model of annualized decline in eGFR\u22653.0 ml\/min per 1.73 m\n 2<\/jats:sup>\n did not improve risk prediction.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions<\/jats:title>\n Higher serum fibroblast growth factor 23 concentration was associated with kidney function decline, height-adjusted total kidney volume percentage increase, and death in patients with autosomal dominant polycystic kidney disease. However, fibroblast growth factor 23 did not substantially improve prediction of rapid kidney function decline.<\/jats:p>\n <\/jats:sec>","DOI":"10.2215\/cjn.12821216","type":"journal-article","created":{"date-parts":[[2017,7,13]],"date-time":"2017-07-13T20:25:32Z","timestamp":1499977532000},"page":"1461-1469","source":"Crossref","is-referenced-by-count":24,"title":["Fibroblast Growth Factor 23 and Kidney Disease Progression in Autosomal Dominant Polycystic Kidney Disease"],"prefix":"10.2215","volume":"12","author":[{"given":"Michel","family":"Chonchol","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Berenice","family":"Gitomer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamara","family":"Isakova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuan","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isidro","family":"Salusky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renata","family":"Pereira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaleab","family":"Abebe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vicente","family":"Torres","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theodor I.","family":"Steinman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jared J.","family":"Grantham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arlene B.","family":"Chapman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert W.","family":"Schrier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Myles","family":"Wolf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2017,7,13]]},"reference":[{"key":"B1-20230813","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1016\/S0140-6736(07)60601-1","article-title":"Autosomal dominant polycystic kidney disease.","volume":"369","author":"Torres","year":"2007","journal-title":"Lancet"},{"key":"B2-20230813","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1016\/S0272-6386(83)80044-4","article-title":"Epidemiology of adult polycystic kidney disease, Olmsted County, Minnesota: 1935-1980.","volume":"2","author":"Iglesias","year":"1983","journal-title":"Am J Kidney Dis"},{"key":"B3-20230813","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1056\/NEJMcp0804458","article-title":"Clinical practice. Autosomal dominant polycystic kidney disease.","volume":"359","author":"Grantham","year":"2008","journal-title":"N Engl J Med"},{"key":"B4-20230813","doi-asserted-by":"crossref","first-page":"2142","DOI":"10.1681\/ASN.V7102142","article-title":"Linkage, clinical features, and prognosis of autosomal dominant polycystic kidney disease types 1 and 2.","volume":"7","author":"Torra","year":"1996","journal-title":"J Am Soc Nephrol"},{"key":"B5-20230813","doi-asserted-by":"crossref","first-page":"2543","DOI":"10.1074\/jbc.M408903200","article-title":"Circulating FGF-23 is regulated by 1alpha,25-dihydroxyvitamin D3 and phosphorus in vivo.","volume":"280","author":"Saito","year":"2005","journal-title":"J Biol Chem"},{"key":"B6-20230813","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1359\/JBMR.0301264","article-title":"FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis.","volume":"19","author":"Shimada","year":"2004","journal-title":"J Bone Miner Res"},{"key":"B7-20230813","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1681\/ASN.2009121293","article-title":"Forging forward with 10 burning questions on FGF23 in kidney disease.","volume":"21","author":"Wolf","year":"2010","journal-title":"J Am Soc Nephrol"},{"key":"B8-20230813","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1038\/ki.2008.643","article-title":"Latest findings in phosphate homeostasis.","volume":"75","author":"Pri\u00e9","year":"2009","journal-title":"Kidney Int"},{"key":"B9-20230813","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1038\/ki.2011.47","article-title":"Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease.","volume":"79","author":"Isakova","year":"2011","journal-title":"Kidney Int"},{"key":"B10-20230813","doi-asserted-by":"crossref","first-page":"640","DOI":"10.7326\/0003-4819-152-10-201005180-00004","article-title":"The associations of fibroblast growth factor 23 and uncarboxylated matrix Gla protein with mortality in coronary artery disease: The Heart and Soul Study.","volume":"152","author":"Parker","year":"2010","journal-title":"Ann Intern Med"},{"key":"B11-20230813","doi-asserted-by":"crossref","first-page":"2432","DOI":"10.1001\/jama.2011.826","article-title":"Fibroblast growth factor 23 and risks of mortality and end-stage renal disease in patients with chronic kidney disease.","volume":"305","author":"Isakova","year":"2011","journal-title":"JAMA"},{"key":"B12-20230813","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1681\/ASN.2010121224","article-title":"FGF-23 associates with death, cardiovascular events and initiation of chronic dialysis.","volume":"22","author":"Kendrick","year":"2011","journal-title":"J Am Soc Nephrol"},{"key":"B13-20230813","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1681\/ASN.2014101009","article-title":"Low vitamin D and high fibroblast growth factor 23 serum levels associate with infectious and cardiac deaths in the HEMO study.","volume":"27","author":"Chonchol","year":"2016","journal-title":"J Am Soc Nephrol"},{"key":"B14-20230813","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1056\/NEJMoa0706130","article-title":"Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis.","volume":"359","author":"Guti\u00e9rrez","year":"2008","journal-title":"N Engl J Med"},{"key":"B15-20230813","doi-asserted-by":"crossref","first-page":"2600","DOI":"10.1681\/ASN.2006080936","article-title":"Fibroblast growth factor 23 (FGF23) predicts progression of chronic kidney disease: The Mild to Moderate Kidney Disease (MMKD) Study.","volume":"18","author":"Fliser","year":"2007","journal-title":"J Am Soc Nephrol"},{"key":"B16-20230813","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1681\/ASN.2014020218","article-title":"Serum fibroblast growth factor-23 is associated with incident kidney disease.","volume":"26","author":"Rebholz","year":"2015","journal-title":"J Am Soc Nephrol"},{"key":"B18-20230813","doi-asserted-by":"crossref","first-page":"29","DOI":"10.2215\/CJN.06190614","article-title":"Fibroblast growth factor 23 and incident CKD in type 2 diabetes.","volume":"10","author":"Isakova","year":"2015","journal-title":"Clin J Am Soc Nephrol"},{"key":"B19-20230813","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1007\/s00467-012-2384-5","article-title":"From bone abnormalities to mineral metabolism dysregulation in autosomal dominant polycystic kidney disease.","volume":"28","author":"Mekahli","year":"2013","journal-title":"Pediatr Nephrol"},{"key":"B20-20230813","doi-asserted-by":"crossref","first-page":"479","DOI":"10.2215\/CJN.09500911","article-title":"Kidney volume and functional outcomes in autosomal dominant polycystic kidney disease.","volume":"7","author":"Chapman","year":"2012","journal-title":"Clin J Am Soc Nephrol"},{"key":"B21-20230813","doi-asserted-by":"crossref","first-page":"2399","DOI":"10.1681\/ASN.2013111184","article-title":"Predictors of autosomal dominant polycystic kidney disease progression.","volume":"25","author":"Schrier","year":"2014","journal-title":"J Am Soc Nephrol"},{"key":"B22-20230813","doi-asserted-by":"crossref","first-page":"102","DOI":"10.2215\/CJN.04310709","article-title":"The HALT polycystic kidney disease trials: Design and implementation.","volume":"5","author":"Chapman","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"key":"B23-20230813","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1056\/NEJMoa1402685","article-title":"Blood pressure in early autosomal dominant polycystic kidney disease.","volume":"371","author":"Schrier","year":"2014","journal-title":"N Engl J Med"},{"key":"B24-20230813","doi-asserted-by":"crossref","first-page":"2267","DOI":"10.1056\/NEJMoa1402686","article-title":"Angiotensin blockade in late autosomal dominant polycystic kidney disease.","volume":"371","author":"Torres","year":"2014","journal-title":"N Engl J Med"},{"key":"B25-20230813","doi-asserted-by":"crossref","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","article-title":"A new equation to estimate glomerular filtration rate.","volume":"150","author":"Levey","year":"2009","journal-title":"Ann Intern Med"},{"key":"B27-20230813","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.1056\/NEJMoa1205511","article-title":"Tolvaptan in patients with autosomal dominant polycystic kidney disease.","volume":"367","author":"Torres","year":"2012","journal-title":"N Engl J Med"},{"key":"B28-20230813","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1111\/j.1365-2362.2007.01913.x","article-title":"Co-inheritance of a PKD1 mutation and homozygous PKD2 variant: A potential modifier in autosomal dominant polycystic kidney disease.","volume":"38","author":"Dedoussis","year":"2008","journal-title":"Eur J Clin Invest"},{"key":"B29-20230813","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1681\/ASN.V661634","article-title":"Factors influencing progression of renal failure in autosomal dominant polycystic kidney disease.","volume":"6","author":"Choukroun","year":"1995","journal-title":"J Am Soc Nephrol"},{"key":"B30-20230813","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1681\/ASN.V8101560","article-title":"Identification of patients with autosomal dominant polycystic kidney disease at highest risk for end-stage renal disease.","volume":"8","author":"Johnson","year":"1997","journal-title":"J Am Soc Nephrol"},{"key":"B32-20230813","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1681\/ASN.2006080894","article-title":"Physiology and pathophysiology of heme: Implications for kidney disease.","volume":"18","author":"Tracz","year":"2007","journal-title":"J Am Soc Nephrol"},{"key":"B33-20230813","doi-asserted-by":"crossref","first-page":"112","DOI":"10.2215\/CJN.00910306","article-title":"Magnetic resonance measurements of renal blood flow and disease progression in autosomal dominant polycystic kidney disease.","volume":"2","author":"Torres","year":"2007","journal-title":"Clin J Am Soc Nephrol"},{"key":"B34-20230813","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1681\/ASN.V561349","article-title":"Overt proteinuria and microalbuminuria in autosomal dominant polycystic kidney disease.","volume":"5","author":"Chapman","year":"1994","journal-title":"J Am Soc Nephrol"},{"key":"B35-20230813","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1038\/ki.2011.411","article-title":"Analysis of baseline parameters in the HALT polycystic kidney disease trials.","volume":"81","author":"Torres","year":"2012","journal-title":"Kidney Int"},{"key":"B36-20230813","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1053\/j.ajkd.2012.08.038","article-title":"Relationship of copeptin, a surrogate marker for arginine vasopressin, with change in total kidney volume and GFR decline in autosomal dominant polycystic kidney disease: Results from the CRISP cohort.","volume":"61","author":"Boertien","year":"2013","journal-title":"Am J Kidney Dis"},{"key":"B37-20230813","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1038\/ki.2010.375","article-title":"Patients with autosomal dominant polycystic kidney disease have elevated fibroblast growth factor 23 levels and a renal leak of phosphate.","volume":"79","author":"Pavik","year":"2011","journal-title":"Kidney Int"},{"key":"B38-20230813","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1038\/ki.2013.526","article-title":"Renal expression of FGF23 and peripheral resistance to elevated FGF23 in rodent models of polycystic kidney disease.","volume":"85","author":"Spichtig","year":"2014","journal-title":"Kidney Int"}],"container-title":["Clinical Journal of the American Society of Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/01277230-201709000-00012","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T13:36:59Z","timestamp":1786369019000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/01277230-201709000-00012"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,7,13]]},"references-count":35,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2017]]}},"URL":"https:\/\/doi.org\/10.2215\/cjn.12821216","relation":{},"ISSN":["1555-9041","1555-905X"],"issn-type":[{"value":"1555-9041","type":"print"},{"value":"1555-905X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,7,13]]}}}